The GLP-1 Market at an Inflection Point: Coverage, Pricing, and the Road Ahead

‍From Supply Crunch to Cash Economy

In a remarkably short window, GLP-1 medications have gone from a niche category to the best-selling drug class in the world. Randhir Vieira, former Chief Product Officer at Omada Health and a longtime operator at the intersection of digital health and chronic disease management, led a recent roundtable discussion assessing where the market stands and what comes next. His analysis covered pricing, access, employer dynamics, oral medications, and the downstream clinical and economic case for long-term treatment.

The first major shift Randhir identified was structural: the compounding era is over. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and enforcement of compounding restrictions has since followed. Volume has shifted to branded and cash channels, and cash pay has become core infrastructure for the category.

The scale of this shift is striking. Roughly one in three new patients starting branded weight management medications in 2025 began on self-pay vials. In response, manufacturers have built direct infrastructure, with Novo Nordisk launching NovoCare and Lilly launching LillyDirect, alongside partnerships with direct-to-consumer platforms including Ro, GoodRx, and Weight Watchers.

Pricing has moved in parallel. Through a combination of Most Favored Nation agreements and the TrumpRx program, cash prices have fallen to around $350 per month, with government-negotiated pricing at approximately $245 for Medicare and Medicaid. The Medicare GLP-1 Bridge program, which launched in July 2026 at a $50 monthly copay, has further expanded access for eligible beneficiaries.

The Bridge Program: Promise and Limitations

Randhir described the Bridge program as genuinely exciting but temporary and imperfect. Running from July 2026 through December 2027, it operates outside of Medicare Part D, meaning plans carry no risk and don't need to opt in.

While roughly 3.8 million Medicare beneficiaries meet the eligibility criteria, the key unknown is how many will actually enroll. Randhir noted that $50, while dramatically lower than historical GLP-1 list prices, is still high relative to what Medicare beneficiaries typically pay for other medications, particularly generics. There is no low-income subsidy available, so for some beneficiaries the price point may still be out of reach.

There are also notable exclusions. Type 2 diabetes patients, those with moderate to severe sleep apnea, and MASH patients are routed to Part D rather than covered under Bridge. The program also has no successor pathway, which raises uncertainty about what happens when it ends for patients who have started treatment and come to depend on that access.

Employers Under Pressure

On the employer side, Randhir described a market under significant cost strain. According to Mercer data he cited, approximately 50%of firms with more than 500 employees now cover GLP-1s for weight loss, up from around 44% previously. Of those not yet covering them, only about 1% say they are likely to add coverage, suggesting the market has largely sorted into two camps and that the coverage plateau may be near.

The cost impact is real. About two thirds of the largest firms report that GLP-1s significantly affect their drug spend, and total health benefit costs are running around $18,000 per employee in 2026. Looking ahead to 2027 renewals, Randhir cited survey data suggesting that somewhere between 5% and 10% of large employers are considering dropping GLP-1 coverage altogether.

For those continuing to cover these medications, utilization management has become a priority. Around 34% of covering firms now require participation in a lifestyle program from companies like Omada, Noom, or 9amHealth as a condition of coverage or refill. Some employers have also moved to narrow networks of designated prescribers and verified biometrics rather than self-reported BMI.

The underlying challenge, Randhir explained, is a timing mismatch. The drugs work, but the downstream savings from avoided cardiovascular events and hospitalizations typically take longer to materialize than the average tenure of an employee on a given health plan. Employers are paying for the intervention while the next plan harvests the benefit. Until that mismatch is resolved, or until drug costs fall far enough to change the math, the ROI case will remain difficult to make within standard benefit cycles.

Adherence, Persistence, and What the Data Shows

Persistence rates have improved substantially. Among patients who started GLP-1 therapy in 2021, only about 33% were still on the medication after one year. For those who started in early 2024, that figure had nearly doubled to 63%, driven by better-tolerated formulations, improved side effect management, and greater patient awareness.

The two most common reasons patients discontinue are gastrointestinal side effects and cost. About 30% of those who quit do so within the first month, and 60% stop before reaching any clinically meaningful benefit. Randhir described the economics of early discontinuation plainly: you pay the cost without receiving the return.

Importantly, discontinuation is not always permanent. Within a year of stopping, roughly 27% of patients either restart their original medication or switch to a different one. Randhir used the analogy of a leaky bucket with a return valve, where patients cycle rather than churn completely. That makes the experience they have with a given drug or manufacturer matter significantly for long-term retention.

Companion lifestyle programs have shown real value in thiscontext, both improving weight loss outcomes during treatment and reducingweight regain after stopping.

The Rise of Oral GLP-1s

Randhir was optimistic about oral GLP-1s, describing their emergence as a market-expanding development rather than a substitution story. Novo Nordisk's Wegovy pill received FDA approval in December 2025, and Eli Lilly's Foundayo followed in April 2026. Both launched at approximately $149 per month in cash.

Early data supports the expansion thesis. The Wegovy pill reached five million prescriptions within its first six to seven months, more than 265,000 per week, and 80% of those patients identified as new to the GLP-1 class entirely. They were not switching from injectables; they were patients who had not previously been willing or able to start therapy. Ninety percent of that volume came through self-pay channels.

Randhir suggested that $149 may represent a pricing threshold that unlocks meaningful pent-up demand, particularly among patients who were deterred by self-injection. He also flagged an emerging behavioral pattern worth watching: patients indicating interest in using injectable therapy to reach a target weight, then transitioning to an oral medication for long-term maintenance. Whether that model becomes common will be one of the more consequential dynamics to track over the next 12 to 18 months.

Novo and Lilly: Diverging Trajectories

In head-to-head clinical data, tirzepatide has shown roughly 20% weight loss compared to approximately 13.5% for semaglutide at 72 weeks,and that efficacy gap has contributed to Lilly's commercial momentum.

When it comes to pills, the competition is closer. Despite only a three-to-four month head start, Novo's Wegovy pill is currently generating around 170,000 weekly prescriptions compared to approximately 35,000 for Lilly's Foundayo. Randhir noted that Lilly has historically started slowly and accelerated, suggesting the gap between the two pills could narrow over time.

Both companies have been cutting cash prices aggressively, from initial levels of roughly $499 down to $299, with some introductory offers at $199, and both orals launched at $149. In Randhir's view, both companies are treating this as a land grab, accepting margin pressure in the near term to lock in as many patients as possible. Lilly's Q2 results illustrated the dynamic clearly: a 60% increase in volume alongside a 13% drop in realized price.

The Downstream Case: Where the Evidence Stands

The clinical argument for GLP-1s as a cardiovascular and metabolic intervention is building. Randhir cited the SELECT trial's 20%relative reduction in major adverse cardiovascular events, the FLOW study's 24% reduction in kidney disease progression, and the SUMMIT trial's 38% reduction in heart failure outcomes. Zepbound also received approval for obstructive sleep apnea. These indications matter strategically because they allow payers to cover a disease rather than weight loss alone.

The fiscal case is less settled. The Congressional Budget Office estimates Medicare obesity coverage costs approximately $5,500 per user per year, against documented health savings offsets of roughly $50. Randhir acknowledged that the math does not work at current parameters, and that either the measurement of downstream savings needs to improve or costs need to continue falling, preferably both.

Some early real-world data is encouraging. An Aon study of approximately 190,000 users found 6 to 9% lower medical costs for diabetic users at 30 months, and 3 to 7% lower costs for weight loss users at 18 months.Randhir described this as promising signal rather than definitive evidence, but an indication that the value case can eventually be made.

The 12-Month Outlook

Randhir closed the discussion with a cautiously optimistic view of the near-term horizon. The Medicare Bridge program will generate important real-world data before its December 2027 end date, and the question of whether a successor program emerges will be central to access policy. Several pipeline readouts, including an FDA decision on CagriSema, are expected within the year and will further shape coverage and indication strategies.

The employer renewal season now underway will be a key signal for whether large-employer coverage holds at current levels or begins the decline that some survey data foreshadows. Pills will continue to expand the patient pool. The launch of international generic semaglutides, already underway in Canada, China, India, and Brazil in 2026, will provide the first real-world data on what adoption looks like at generic price points.

The broader market trajectory remains compelling. Morgan Stanley projects the category growing from approximately $80 billion in 2025 to close to $200 billion by 2035. IQVIA forecasts $92 billion in 2026 and expects GLP-1s to rank among the top five therapy classes globally by 2030. After years of treating obesity as a lifestyle issue rather than a disease, the clinical, commercial, and policy infrastructure to address it at scale is finally taking shape, and the category is still in its early chapters.

‍